Citations (80)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yao Chen, Xuejiao Qie, Wei Quan, Maomao Zeng, Fang Qin, Jie Chen, Benu Adhikari & Zhiyong He. (2023) Omnifarious fruit polyphenols: an omnipotent strategy to prevent and intervene diabetes and related complication?. Critical Reviews in Food Science and Nutrition 63:20, pages 4288-4324.
Read now
Read now
Tada Kunavisarut, Sutin Sriussadaporn & Raweewan Lertwattanarak. (2019) Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea. Diabetes, Metabolic Syndrome and Obesity 12, pages 761-770.
Read now
Read now
Philip A Levin. (2016) Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 9, pages 355-369.
Read now
Read now
Nancy J. V. Bohannon. (2012) Individualized Treatment of Type 2 Diabetes Mellitus Using Noninsulin Agents: Clinical Considerations for the Primary Care Physician. Postgraduate Medicine 124:4, pages 95-108.
Read now
Read now
Articles from other publishers (76)
Upasana R. Yadav, Kothula Devender, M. Poornima, Cheemalamarri Chandra Sekhar, Krishnam Raju Atcha, B．V． Subba Reddy & Pannala Padmaja. (2024) Design, synthesis and biological evaluation of triazole, sulfonamide and sulfonyl urea derivatives of N-acylhomoserine lactone as quorum sensing inhibitors. Journal of Molecular Structure 1295, pages 136547.
Crossref
Crossref
Haiwen Li, Obaid Ullah Beg, Ahmed Reza Rafie, Sadia Kanwal, Alexandra Ovalle-Cisneros, Milton Omar Faison & Rafat Ali Siddiqui. (2023) Characterization of Green and Yellow Papaya (Carica papaya) for Anti-Diabetic Activity in Liver and Myoblast Cells and Wound-Healing Activity in Fibroblast Cells. Nutrients 15:8, pages 1929.
Crossref
Crossref
Qing Zhang, Yuying Qi, Shuanghu Wang, Fangling Zhao, Lili Zou, Quan Zhou, Peiwu Geng, Yun Hong, Hang Yang, Qingfeng Luo, Jianping Cai, Hualan Wu, Dongxu Wang, Hao Chen, Jiefu Yang & Dapeng Dai. (2023) Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects. Frontiers in Endocrinology 14.
Crossref
Crossref
Maliha Sarfraz, Rahman M. Hafizur, Hayat Ullah, Sanaullah Sajid, Rana Waseem Akhtar, Mamoona Noreen, Shazia Perveen & Misbah Ullah Khan. 2023. Frontiers in Clinical Drug Research-Diabetes and Obesity: Volume 7. Frontiers in Clinical Drug Research-Diabetes and Obesity: Volume 7
22
47
.
Russell W. Fankhouser, Derek E. Murrell, Yaa Y. Anane, David L. Hurley, Hadii M. Mamudu & Sam Harirforoosh. (2022) Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers. Drug Metabolism and Personalized Therapy 37:4, pages 375-382.
Crossref
Crossref
Zeynep Gizem Todurga Seven, Deniz Özen & Sibel Özyazgan. 2022. Biomarkers in Medicine. Biomarkers in Medicine
309
377
.
Nicolas Cottura, Hannah Kinvig, Sandra Grañana‐Castillo, Adam Wood & Marco Siccardi. (2022) Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives. The Journal of Clinical Pharmacology 62:7, pages 835-846.
Crossref
Crossref
Hua-Lin Zhou, Richard T. Premont & Jonathan S. Stamler. (2021) The manifold roles of protein S-nitrosylation in the life of insulin. Nature Reviews Endocrinology 18:2, pages 111-128.
Crossref
Crossref
Ke Wang, Aimin Yang, Mai Shi, Claudia C. H. Tam, Eric S. H. Lau, Baoqi Fan, Cadmon K. P. Lim, Heung Man Lee, Alice P. S. Kong, Andrea O. Y. Luk, Brian Tomlinson, Ronald C. W. Ma, Juliana C. N. Chan & Elaine Chow. (2021)
CYP2C19
Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes
. Clinical Pharmacology & Therapeutics 111:2, pages 461-469.
Crossref
Crossref
Michael K. Danquah & Jaison Jeevanandam. 2022. Emerging Nanomedicines for Diabetes Mellitus Theranostics. Emerging Nanomedicines for Diabetes Mellitus Theranostics
1
31
.
Katy Sánchez-Pozos, María de los Ángeles Granados-Silvestre & María Guadalupe Ortíz-López. 2021. Drug Metabolism. Drug Metabolism.
Leyla Karkhaneh, Ozra Tabatabaei-Malazy, Fatemeh Bandarian, Shahrzad Mohseni & Bagher Larijani. (2021) Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review. Journal of Diabetes & Metabolic Disorders 21:1, pages 863-879.
Crossref
Crossref
Jieun Kim, Jin-Hee Park, Keshvi Shah, Scott John Mitchell, Kwangwook Cho & Hyang-Sook Hoe. (2021) The Anti-diabetic Drug Gliquidone Modulates Lipopolysaccharide-Mediated Microglial Neuroinflammatory Responses by Inhibiting the NLRP3 Inflammasome. Frontiers in Aging Neuroscience 13.
Crossref
Crossref
Cécile Fokoun, Hassan Serrier, Hugo Rabier, Sylvain Goutelle, Michel Tod & Laurent Bourguignon. (2021) Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. The Pharmacogenomics Journal 21:5, pages 559-565.
Crossref
Crossref
Jana Blahova, Monika Martiniakova, Martina Babikova, Veronika Kovacova, Vladimira Mondockova & Radoslav Omelka. (2021) Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus. Pharmaceuticals 14:8, pages 806.
Crossref
Crossref
Toktam Sahranavard, Federico Carbone, Fabrizio Montecucco, Suowen Xu, Khalid Al‐Rasadi, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2020) The role of potassium in atherosclerosis. European Journal of Clinical Investigation 51:3.
Crossref
Crossref
Arjun K. Fontaine, David G. Ramirez, Samuel F. Littich, Robert A. Piscopio, Vira Kravets, Wolfgang E. Schleicher, Naoko Mizoguchi, John H. Caldwell, Richard F. ff. Weir & Richard K. P. Benninger. (2021) Optogenetic stimulation of cholinergic fibers for the modulation of insulin and glycemia. Scientific Reports 11:1.
Crossref
Crossref
Hiroyuki Kurata. (2021) Virtual metabolic human dynamic model for pathological analysis and therapy design for diabetes. iScience 24:2, pages 102101.
Crossref
Crossref
Imadeldin Elfaki, Rashid Mir, Faisel Mohammed Abu-Duhier, Chandan Kumar Jha, Adel Ibrahim Ahmad Al-Alawy, Abdullatif Taha Babakr & Salem Abd El-Hadi Habib. (2020) Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study. Current Drug Metabolism 21:14, pages 1152-1160.
Crossref
Crossref
Sabrina L. Mitchell, Daniel A. Carranza Leon, Sandip Chaugai, Vivian K. Kawai, Rebecca T. Levinson, Wei-Qi Wei & C. Michael Stein. (2020) Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. The Pharmacogenomics Journal 20:6, pages 831-839.
Crossref
Crossref
Kritika Singh, Praveen Kumar Tripathi, Vinay Kumar Singh, Ashok Kumar Patel, O. N. Srivastava, S. K. Singh & Arvind M. Kayastha. (2019) In Silico Analysis of New Potent Anti-hyperglycemic Molecule for Diabetes Type 2 Management. International Journal of Peptide Research and Therapeutics 26:2, pages 1031-1042.
Crossref
Crossref
Wei Lv, Xianqing Wang, Qian Xu & Wencong Lu. (2020) Mechanisms and Characteristics of Sulfonylureas and Glinides. Current Topics in Medicinal Chemistry 20:1, pages 37-56.
Crossref
Crossref
Mohammad Ishraq Zafar. (2020) Suitability of APINCH high-risk medications use in diabetes mellitus. European Journal of Pharmacology 867, pages 172845.
Crossref
Crossref
Mahesh Sreekantan Krishna & Karthika Bahulayan Arun. 2020. Plant-derived Bioactives. Plant-derived Bioactives
259
277
.
Yulia A Nasykhova, Yury A Barbitoff, Elena A Serebryakova, Dmitry S Katserov & Andrey S Glotov. (2019) Recent advances and perspectives in next generation sequencing application to the genetic research of type 2 diabetes. World Journal of Diabetes 10:7, pages 376-395.
Crossref
Crossref
Yihan Wang, Leo M. Hall, Marisa Kujawa, Hainan Li, Xiang Zhang, Megan O’Meara, Tomomi Ichinose & Jie-Mei Wang. (2019)
Methylglyoxal triggers human aortic endothelial cell dysfunction via modulation of the K
ATP
/MAPK pathway
. American Journal of Physiology-Cell Physiology 317:1, pages C68-C81.
Crossref
Crossref
Sushma Verma, Saliha Rizvi, Mohd Abbas, Tasleem Raza & Farzana Mahdi. (2019) Personalized medicine- future of diagnosis and management of T2DM. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:4, pages 2425-2430.
Crossref
Crossref
Sebastian Niezen, Humberto Diaz del Castillo, Lumen A. Mendez Castaner & Alessia Fornoni. (2019) Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease. Endocrinology, Diabetes & Metabolism 2:3.
Crossref
Crossref
Richa Dubey, Ketaki Patil, Sarath C. DantuDevika M. Sardesai, Parnika Bhatia, Nikita Malik, Jhankar D. Acharya, Soham Sarkar, Soumadwip Ghosh, Rajarshi Chakrabarti, Shilpy Sharma & Ashutosh Kumar. (2019) Azadirachtin inhibits amyloid formation, disaggregates pre-formed fibrils and protects pancreatic β-cells from human islet amyloid polypeptide/amylin-induced cytotoxicity. Biochemical Journal 476:5, pages 889-907.
Crossref
Crossref
Tet Soon Wong, Hassan Fahmi Ismail, Zanariah Hashim & Fadzilah Adibah Abdul Majid. (2019) Synergistic antihyperglycaemic effect of combination therapy with gallic acid and andrographolide in streptozotocin-induced diabetic rats. Biocatalysis and Agricultural Biotechnology 18, pages 101048.
Crossref
Crossref
Andrew Whang, Ravinder Nagpal & Hariom Yadav. (2019) Bi-directional drug-microbiome interactions of anti-diabetics. EBioMedicine 39, pages 591-602.
Crossref
Crossref
Y. W. Francis Lam, Ravindranath Duggirala, Christopher P. Jenkinson & Rector Arya. 2019. Pharmacogenomics. Pharmacogenomics
247
269
.
Yu Chen, Lin Chen, Hong Zhang, Shibo Huang, Yuqing Xiong & Chunhua Xia. (2018) Interaction of Sulfonylureas with Liver Uptake Transporters OATP1B1 and OATP1B3. Basic & Clinical Pharmacology & Toxicology 123:2, pages 147-154.
Crossref
Crossref
Kyung Young Lee, Jae-Ryong Kim & Hyoung Chul Choi. (2018) Gliclazide, a K ATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKKβ–AMPK pathway. Vascular Pharmacology 102, pages 21-28.
Crossref
Crossref
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, PradeepK Shrestha, Aravinthan Mahalingam, Mazen Askheta, AlyAhmed A. Rahim, Fatimah Eliana, HariK Shrestha, Sandeep Chaudhary, Nancy Ngugi, JeanClaude Mbanya, ThanThan Aye, TintSwe Latt, ZhanayA Akanov, AbbasRaza Syed, Nikhil Tandon, AG Unnikrishnan, SV Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj & AshokKumar Das. (2018) Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force. Indian Journal of Endocrinology and Metabolism 22:1, pages 132.
Crossref
Crossref
Jingwen Song, Yunzhong Yang, Franck Mauvais-Jarvis, Yu-Ping Wang & Tianhua Niu. (2017) KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment. BMC Medical Genetics 18:1.
Crossref
Crossref
Manodeep Chakraborty, Mohammed Gulzar Ahmed & Ananya Bhattacharjee. (2017) The potential for interaction of tolbutamide with pomegranate juice against diabetic induced complications in rats. Integrative Medicine Research 6:4, pages 354-360.
Crossref
Crossref
A Surendiran, V Saranya & N Anusha. (2018) Pharmacogenomics of Type 2 Diabetes Mellitus. SBV Journal of Basic, Clinical and Applied Health Science 1:A1, pages 6-19.
Crossref
Crossref
K. H. Ha, B. Kim, H. Choi, D. J. Kim & H. C. Kim. (2017) Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. Diabetic Medicine 34:9, pages 1235-1243.
Crossref
Crossref
Nina Elk & Otito F. Iwuchukwu. (2017) Using Personalized Medicine in the Management of Diabetes Mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:9, pages 1131-1149.
Crossref
Crossref
Se E. Park, Byung W. Lee, Jae H. Kim, Woo J. Lee, Jae H. Cho, Chang H. Jung, Seung H. Lee, Sunghwan Suh, Gwong C. Hur, Sung H. Kim, Young H. Jang & Cheol Y. Park. (2017) Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). Diabetes, Obesity and Metabolism 19:6, pages 892-896.
Crossref
Crossref
Karla Salgado-Puga, Javier Rodríguez-Colorado, Roberto A. Prado-Alcalá & Fernando Peña-Ortega. (2017) Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid-β. Journal of Alzheimer's Disease 57:1, pages 205-226.
Crossref
Crossref
X. Li & Z.Q. Liu. 2017. Drug Metabolism in Diseases. Drug Metabolism in Diseases
157
179
.
Jagdeep S. S. Singh, Amir Fathi, Keeran Vickneson, Ify Mordi, Mohapradeep Mohan, J. Graeme Houston, Ewan R. Pearson, Allan D. Struthers & Chim C. Lang. (2016) Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology 15:1.
Crossref
Crossref
Katy Sánchez-Pozos, Carolina Rivera-Santiago, María Helena García-Rodríguez, María Guadalupe Ortiz-López, Barbara Itzel Peña-EspinozaMaría de los Ángeles Granados-Silvestre, Adrian Llerena & Marta Menjívar. (2016)
Genetic variability of
CYP2C9*2
and
CYP2C9*3
in seven indigenous groups from Mexico
. Pharmacogenomics 17:17, pages 1881-1889.
Crossref
Crossref
Prachi Gupta, Manju Bala, Sanjeev Gupta, Anita Dua, Rajesh Dabur, Elisha Injeti & Ashwani Mittal. (2016) Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action. Pharmacological Research 113, pages 636-674.
Crossref
Crossref
Wotan Zeng, Yali Guo, Peixian Chen, Zhike Liu, Dafang Chen & Chunji Han. (2016)
CYP
2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients
. Journal of Diabetes Investigation 7:5, pages 764-768.
Crossref
Crossref
Qian RenDi XiaoXueyao HanStacey L. EdwardsHuaiqing WangYong TangSimin ZhangXi LiXiuying ZhangXiaoling CaiZhaoqian LiuSanjoy K. PaulLinong Ji. (2016) Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics 18:9, pages 586-593.
Crossref
Crossref
Valerio Costa, Antonio Federico, Carla Pollastro, Carmela Ziviello, Simona Cataldi, Pietro Formisano & Alfredo Ciccodicola. (2016) Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes. International Journal of Molecular Sciences 17:7, pages 1008.
Crossref
Crossref
N K Loganadan, H Z Huri, S R Vethakkan & Z Hussein. (2016) Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. The Pharmacogenomics Journal 16:3, pages 209-219.
Crossref
Crossref
Fangfang Duan, Yali Guo, Liuwei Zhang, Peixian Chen, Xiaozhu Wang, Zhike Liu, Yonghua Hu, Shenren Chen & Dafang Chen. (2016) Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients. Pharmacogenetics and Genomics 26:4, pages 178-183.
Crossref
Crossref
Henk den Ouden, Linette Pellis, Guy E. H. M. Rutten, Ilse K. Geerars-van Vonderen, Carina M. Rubingh, Ben van Ommen, Marjan J. van Erk & Joline W. J. Beulens. (2016) Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. Metabolomics 12:2.
Crossref
Crossref
Khalid Siddiqui & Shivani Tyagi. (2015) Genetics, genomics and personalized medicine in Type 2 diabetes: a perspective on the Arab region. Personalized Medicine 12:4, pages 417-431.
Crossref
Crossref
Dianne Heloisa Bonfanti, Larissa Pontes Alcazar, Priscila Akemi Arakaki, Laysa Toschi Martins, Bruna Carla Agustini, Fabiane Gomes de Moraes Rego & Henrique Ravanhol Frigeri. (2015) ATP-dependent potassium channels and type 2 diabetes mellitus. Clinical Biochemistry 48:7-8, pages 476-482.
Crossref
Crossref
Sanjay Bharti & Debarshi Mahapatra. 2015. Physical Chemistry Research for Engineering and Applied Sciences, Volume Three. Physical Chemistry Research for Engineering and Applied Sciences, Volume Three
121
151
.
Carla Pollastro, Carmela Ziviello, Valerio Costa & Alfredo Ciccodicola. (2015) Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?. PPAR Research 2015, pages 1-10.
Crossref
Crossref
Jonathan Nowak & Lynn Bry. 2015. Genomic Applications in Pathology. Genomic Applications in Pathology
259
276
.
Yanping Li, Yang Hu, Sylvia H. Ley, Swapnil Rajpathak & Frank B. Hu. (2014) Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women. Diabetes Care 37:11, pages 3106-3113.
Crossref
Crossref
Inês Sebastião, Emanuel Candeias, Maria S. Santos, Catarina R. de Oliveira, Paula I. Moreira & Ana I. Duarte. (2014) Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease – How Anti-Diabetics Could be a Solution for Dementia. Frontiers in Endocrinology 5.
Crossref
Crossref
Wen-Ling Liao & Fuu-Jen Tsai. (2014) Personalized medicine in Type 2 Diabetes. BioMedicine 4:2.
Crossref
Crossref
Anette P. Gjesing, Malene Hornbak, Kristine H. Allin, Claus T. Ekstrøm, Søren A. Urhammer, Hans Eiberg, Oluf Pedersen & Torben Hansen. (2014) High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients. Diabetologia 57:6, pages 1173-1181.
Crossref
Crossref
Gábor Winkler. (2014) The use of gliclazide in the mirror of the individualized sulfonylurea therapy. Orvosi Hetilap 155:14, pages 541-548.
Crossref
Crossref
Jasna Klen, Vita Dol?an & Andrej Jane?. (2014) CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European Journal of Clinical Pharmacology 70:4, pages 421-428.
Crossref
Crossref
Henriette E. Meyer zu Schwabedissen, Kerstin Boettcher, Tobias Steiner, Ute I. Schwarz, Markus Keiser, Heyo K. Kroemer & Werner Siegmund. (2014) OATP1B3 Is Expressed in Pancreatic β-Islet Cells and Enhances the Insulinotropic Effect of the Sulfonylurea Derivative Glibenclamide. Diabetes 63:2, pages 775-784.
Crossref
Crossref
N. van Leeuwen, J. J. Swen, H.-J. Guchelaar & L. M. ’t Hart. (2013) The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs. Clinical Pharmacokinetics 52:10, pages 833-854.
Crossref
Crossref
N I Chepliaeva. (2013) Glibenclamide: proven facts, perspectives, discussions. Problems of Endocrinology 59:3, pages 57-62.
Crossref
Crossref
Wen-Ling Liao & Fuu-Jen Tsai. (2013) Personalized medicine: A paradigm shift in healthcare. BioMedicine 3:2, pages 66-72.
Crossref
Crossref
Thaïs Rouquet, Marion S Bonnet, Clément Pierre, Michel Dallaporta, Jean-Denis Troadec, Julien Roux & Bruno Bariohay. (2013) The central question of type 2 diabetes. Pharmaceutical Patent Analyst 2:3, pages 399-427.
Crossref
Crossref
Carlos A. Aguilar-Salinas, Linda Liliana Muñoz-Hernandez, Monica Cobos-Bonilla, Marcos Rafael Ramírez-Márquez, Maria Luisa Ordoñez-Sanchez, Roopa Mehta, Roberto Medina-Santillan & Maria Teresa Tusie-Luna. (2013) The R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus. Metabolism 62:5, pages 638-641.
Crossref
Crossref
E. van de Steeg, R. Greupink, M. Schreurs, I.H.G. Nooijen, K.C.M. Verhoeckx, R. Hanemaaijer, D. Ripken, M. Monshouwer, M.L.H. Vlaming, J. DeGroot, M. Verwei, F.G.M. Russel, M.T. Huisman & H.M. Wortelboer. (2013) Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1. Drug Metabolism and Disposition 41:3, pages 592-601.
Crossref
Crossref
Christina L. Aquilante & Y.W. Francis Lam. 2013. Pharmacogenomics. Pharmacogenomics
247
271
.
Sandhiya Selvarajan, Melvin George & Suresh Kumar Srinivasamurthy. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine
561
573
.
Huali Zhou, Chengjiang Li, Jun Li, Hongtian Yao, Rong Su, Wenpeng Li & Mingzhi Xu. (2012) Associations of ATP-Binding Cassette Transporter A1 and G1 With Insulin Secretion in Human Insulinomas. Pancreas 41:6, pages 934-939.
Crossref
Crossref
Nora NikolacAna-Maria SimundicAndrea SaracevicDarko Katalinic. (2012)
ABCC8
Polymorphisms Are Associated with Triglyceride Concentration in Type 2 Diabetics on Sulfonylurea Therapy
. Genetic Testing and Molecular Biomarkers 16:8, pages 924-930.
Crossref
Crossref
F. Andreelli, D. Jacquier, A. Dierick-Gallet & C. Amouyal. (2011) Pharmacogénétique des antidiabétiques. Médecine des Maladies Métaboliques 5:5, pages 512-519.
Crossref
Crossref
Cheng-Jiang Li, Hua-Li Zhou, Jun Li, Hong-Tian Yao, Rong Su & Wen-Peng Li. (2011) Roles of sulfonylurea receptor 1 and multidrug resistance protein 1 in modulating insulin secretion in human insulinoma. Hepatobiliary & Pancreatic Diseases International 10:1, pages 88-94.
Crossref
Crossref